Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis.

Humans Incidence Observational Studies as Topic / methods Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / diagnosis Prevalence
Chronic inflammatory demyelinating polyradiculoneuropathy Incidence Meta-analysis Prevalence Systematic review

Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2019
Historique:
received: 16 04 2018
accepted: 02 10 2018
pubmed: 23 1 2019
medline: 26 12 2019
entrez: 23 1 2019
Statut: ppublish

Résumé

Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence. A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates. Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria. These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.

Sections du résumé

BACKGROUND
Prevalence and incidence rates of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are required to determine the impact of CIDP on society. We aimed to estimate the prevalence and incidence of CIDP worldwide and to determine the effect of diagnostic criteria on prevalence and incidence.
METHOD
A systematic review was conducted for all published incidence and prevalence studies on CIDP until May 18, 2017. Methodological quality was assessed using the Methodological Evaluation of Observational Research checklist. We performed a random effect meta-analysis to estimate pooled prevalence and incidence rates.
RESULTS
Of the 907 studies, 11 were included in the systematic review, 5 in the meta-analysis of incidence (818 cases; 220,513,514 person-years) and 9 in the meta-analysis of prevalence (3,160 cases; 160,765,325 population). These studies had a moderate quality. The pooled crude incidence rate was 0.33 per 100,000 person-years (95% CI 0.21-0.53; I2 = 95.7%) and the pooled prevalence rate was 2.81 per 100,000 (95% CI 1.58-4.39; I2 = 99.1%). Substantial heterogeneity in incidence and prevalence across studies seems to be partly explained by using different diagnostic criteria.
CONCLUSION
These findings provide a starting point to estimate the social burden of CIDP and demonstrate the need to reach consensus on diagnostic criteria for CIDP.

Identifiants

DOI: 10.1159/000494291 PMID: 30669140 PMC: PMC6518865
pubmed: 30669140
pii: 000494291
doi: 10.1159/000494291
pmc: PMC6518865
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

161-172

Informations de copyright

© 2019 The Author(s) Published by S. Karger AG, Basel.

Références

J Neurol Neurosurg Psychiatry. 2009 Dec;80(12):1364-8
pubmed: 19622522
Neurology. 2007 May 8;68(19):1622-9
pubmed: 17485651
Muscle Nerve. 2011 Jun;43(6):780-94
pubmed: 21607962
Neurology. 2010 Aug 31;75(9):818-25
pubmed: 20805527
Ann Neurol. 1999 Dec;46(6):910-3
pubmed: 10589544
JAMA Neurol. 2017 Oct 1;74(10):1190-1198
pubmed: 28806453
N Engl J Med. 2005 Mar 31;352(13):1343-56
pubmed: 15800230
Eur Neurol. 2016;75(5-6):263-8
pubmed: 27211228
J Diabetes Complications. 2016 Sep-Oct;30(7):1401-7
pubmed: 27389526
J Peripher Nerv Syst. 2014 Mar;19(1):2-13
pubmed: 24612201
J Neurol Neurosurg Psychiatry. 2007 Dec;78(12):1349-53
pubmed: 17494979
J Neurol Sci. 2016 Oct 15;369:204-209
pubmed: 27653889
Rheumatology (Oxford). 2017 Nov 1;56(11):1945-1961
pubmed: 28968809
Eur J Epidemiol. 2016 Jan;31(1):5-20
pubmed: 26700499
PLoS One. 2012;7(10):e48078
pubmed: 23133550
Muscle Nerve. 2014 Jul;50(1):47-51
pubmed: 24639235
J Clin Endocrinol Metab. 2016 Jul;101(7):2826-35
pubmed: 27172433
J Orofac Pain. 2013 Spring;27(2):99-110
pubmed: 23630682
Eur J Neurol. 2014;21(1):28-33
pubmed: 23679015
J Neurol Neurosurg Psychiatry. 1999 May;66(5):677-80
pubmed: 10209187
J Neurotrauma. 2018 Dec 19;:
pubmed: 26537996
Clin Epidemiol. 2014 Jul 30;6:247-55
pubmed: 25114590
J Peripher Nerv Syst. 2010 Dec;15(4):326-33
pubmed: 21199104
J Neuromuscul Dis. 2017;4(2):127-137
pubmed: 28505979
Neurology. 2015 Jan 20;84(3):259-64
pubmed: 25503982
Eur J Neurol. 2006 Apr;13(4):326-32
pubmed: 16643309
J Oral Rehabil. 2013 Aug;40(8):631-42
pubmed: 23700983
J Clin Epidemiol. 2011 Jun;64(6):637-57
pubmed: 21071174
Eur J Neurol. 2007 Jun;14(6):603-8
pubmed: 17539935
Muscle Nerve. 2014 Jul;50(1):40-6
pubmed: 24338746
J Peripher Nerv Syst. 2010 Mar;15(1):1-9
pubmed: 20433600
Ann Neurol. 2001 Aug;50(2):195-201
pubmed: 11506402
Neurology. 1991 May;41(5):617-8
pubmed: 2027473
Neurology. 2003 Apr 1;60(8 Suppl 3):S8-15
pubmed: 12707417
Muscle Nerve. 2009 Apr;39(4):432-8
pubmed: 19260065
Neurology. 2009 Jul 7;73(1):39-45
pubmed: 19564582
Neurology. 1997 Feb;48(2):321-8
pubmed: 9040714
Cochrane Database Syst Rev. 2017 Jan 13;1:CD010369
pubmed: 28084646
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
J Peripher Nerv Syst. 2009 Dec;14(4):310-5
pubmed: 20021573
Brain. 1987 Dec;110 ( Pt 6):1617-30
pubmed: 3427403
PLoS One. 2013 Jun 19;8(6):e66435
pubmed: 23840467
Lancet Neurol. 2010 Apr;9(4):402-12
pubmed: 20298964
Mayo Clin Proc. 1975 Nov;50(11):621-37
pubmed: 1186294
J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1118-1119
pubmed: 29175895
Ann Rheum Dis. 2015 Jan;74(1):65-73
pubmed: 23999006
Neuromuscul Disord. 2016 Jul;26(7):447-52
pubmed: 27212207
Neurology. 2017 Jan 17;88(3):304-313
pubmed: 27927941
J Neurol Neurosurg Psychiatry. 2008 Sep;79(9):1040-3
pubmed: 18223015
Muscle Nerve. 1989 Jun;12(6):435-51
pubmed: 2657418
J Neuromuscul Dis. 2015;2(1):73-85
pubmed: 28198707
Muscle Nerve. 2001 Mar;24(3):311-24
pubmed: 11353415
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
Nat Rev Neurol. 2011 Nov 22;8(1):48-58
pubmed: 22105211
Neurol Res. 2012 Dec;34(10):960-6
pubmed: 23146298
Eur J Neurol. 2001 Mar;8(2):157-65
pubmed: 11284994
Psychiatry Clin Neurosci. 1995 Jun;49(3):169-74
pubmed: 8612191

Auteurs

Merel C Broers (MC)

Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, m.broers@erasmusmc.nl.

Carina Bunschoten (C)

Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Daan Nieboer (D)

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Hester F Lingsma (HF)

Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Bart C Jacobs (BC)

Department of Neurology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Incidence and Prevalence of Chronic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Incidence and Prevalence of Chronic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Études observationnelles comme sujet › Incidence and Prevalence of Chronic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Polyradiculonévrite inflammatoire démyélinisante chronique › Incidence and Prevalence of Chronic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Prévalence › Incidence and Prevalence of Chronic...